Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC5A7 | Q9GZV3 | 8/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283894 | 0.81 | VHL (0.49) | EPHX2LMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5287986 | 0.81 | SMN1; SMN2 (0.37) | LMNAALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5520474 | 0.76 | LMNA (0.47) | EPHX2LMNAALDH1A1SLC5A7SMN1; SMN2 | |
| SCHEMBL5966687 | 0.75 | SMN1; SMN2 (0.40) | EPHX2LMNAALDH1A1SMN1; SMN2ATM | |
| SCHEMBL5286842 | 0.75 | NOTUM (0.51) | LMNAALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2306096 | 0.68 | LMNA (0.45) | EPHX2LMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL92807 | 0.66 | EPHX2 (0.42) | EPHX2LMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5289527 | 0.66 | SCD (0.31) | EPHX2LMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL13430904 | 0.65 | RAB9A (0.41) | EPHX2LMNAALDH1A1SLC5A7SMN1; SMN2 | |
| SCHEMBL20852655 | 0.65 | EPHX2 (0.40) | EPHX2LMNAALDH1A1SLC5A7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | EPHX2 4143/4885LMNA 3704/4885ALDH1A1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.